Sensei biotherapeutics to present new preclinical data for sns-101, a conditionally active vista-blocking antibody, at the keystone symposia on next generation antibody therapeutics

Boston, feb. 14, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on sns-101, a conditionally active, ph-selective vista-blocking antibody, at next generation antibody therapeutics: from discovery to patient, organized by keystone symposia, being held february 19-22, 2023 in banff, alberta, canada. the presentation will be made by sensei's chief scientific officer, dr. edward van der horst.
SNSE Ratings Summary
SNSE Quant Ranking